A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
ACTIVE_NOT_RECRUITING
Status
Conditions
- Hepatocellular Carcinoma
- Biliary Tract Cancer
Interventions
- DRUG: Nivolumab or pembrolizumab
Sponsor
Asan Medical Center